Sofinnova Partners at BIO-Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
Sofinnova Partners takes part in 3 sessions at BIO-Europe 2026 in Cologne. Its sessions cover early-stage biotech investment, cell and gene therapy, and AI in drug research. One asks why the efficiency AI brings to the lab could mean more drugs rather than fewer research jobs.
| Organization | BIO-Europe 2026 Attendance |
|---|---|
Sofinnova Partners Paris, France | |
Life sciences venture capital firm investing from seed to late stage in biotech, medtech and industrial biotech. | Panel Mon Nov 9 17:00–17:45 AI in the Lab: Why Greater Efficiency Could Mean More Drugs, Not Fewer Scientists Why AI that forms hypotheses and guides experiments could mean more drug candidates, not fewer scientists, and how to pick which to pursue. Ecosystem InnovationBusiness of Biotech Panel Mon Nov 9 16:00–16:45 Cell and Gene Therapy: What Should You Know? Where cell and gene therapies stand today, what recent clinical and sales data show, and how funding and partnerships are changing. Panel Mon Nov 9 16:00–16:45 Fuelling Innovation: The State of Early-Stage Investment in Biotech Investors and founders discuss how young biotech startups raise early funding today and how venture investors' priorities are shifting. |
Instantly find 20 buyers from Sofinnova Partners
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EBD Group, Informa Connect or BIO-Europe. Submit a correction